Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences (EW) insider activity: On 08/18/2025, Larry L. Wood, Global President TAVR & Surg, reported option exercise and related open-market sales under a Rule 10b5-1 plan. He acquired 8,950 shares via exercise of employee stock options at an exercise price of $59.2567 and then sold 8,950 shares in multiple trades at a weighted average sale price of $78.0647.
Following these transactions, the filing shows Mr. Wood beneficially owns 215,850.3913 shares after the acquisition and 206,900.3913 after the sale; an additional 148.1703 shares are held indirectly in a 401(k). The 10b5-1 plan was adopted on February 27, 2025, and the report is signed by an attorney-in-fact on 08/18/2025.
Edwards Lifesciences (EW) Form 144 notice: An insider proposes a routine sale of 8,950 common shares through Charles Schwab & Co., with an aggregate market value of $698,679.00. The shares were acquired on 08/18/2025 via an employee stock option exercise and the planned sale date is listed as 08/18/2025. The filer previously sold 8,950 shares on 06/16/2025 for gross proceeds of $673,268.00. Outstanding shares are listed as 587,100,000, making this transaction immaterial relative to total shares outstanding.
Wellington Management reports beneficial ownership of 19,826,483 shares of Edwards Lifesciences common stock, equal to 3.38% of the class. The filing shows shared voting power of 18,601,111 shares and shared dispositive power of 19,826,483 shares, while sole voting and dispositive power are reported as zero. The securities are owned of record by clients of Wellington investment advisers.
The filing names the reporting entities (Wellington Management Group LLP; Wellington Group Holdings LLP; Wellington Investment Advisors Holdings LLP) and lists the Wellington investment advisers that control the client accounts. It also includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Edwards Lifesciences (EW) Q2 2025 10-Q highlights
Net sales rose 12% YoY to $1.53 bn, driven by transcatheter valve therapies, lifting 1H revenue to $2.95 bn (+9%). Gross margin slipped 240 bp to 77.5% on mix and higher manufacturing cost, but operating income still advanced 12% to $411 m helped by $21 m of TSA income from the September 2024 Critical Care divestiture. A $47 m impairment on an unexercised acquisition option and a sharply higher tax provision ($64 m vs $20 m) cut continuing-ops net income 8% to $336 m; diluted EPS fell to $0.56 (-8%).
Discontinued operations (Critical Care & one minor product line) logged a $4 m loss vs a $1 m profit last year. Combined, GAAP net income attributable to EW declined 9% to $333 m.
Cash & balance sheet
- Operating cash flow surged 79% YoY to $571 m on working-capital improvements.
- Cash & equivalents climbed to $3.27 bn; total liquidity (cash + ST investments) is $4.06 bn.
- Total liabilities fell 4% to $2.88 bn; net cash position of ~$2.7 bn.
Capital allocation & restructuring
- Repurchased $264 m of stock (-3% share count YoY); treasury stock at cost now $6.46 bn.
- Realignment severance reserve down to $10 m; majority of payments due 2H 25.
Key takeaways: Top-line momentum and robust cash generation underline core valve franchises, while EPS was pressured by non-recurring impairment and taxes. Post-divestiture focus on structural-heart pipeline and optionality from sizeable cash balance remain central to the investment case.
Edwards Lifesciences (EW) – Form 4 insider transaction
Company Vice President, JAPAC, Daniel J. Lippis reported the sale of 4,114 EW common shares on 07/28/2025. Trades were executed in multiple lots at prices between $79.45 and $79.47, producing a weighted-average sale price of $79.4605. Following the sale, Lippis’ direct beneficial ownership stands at 22,001.9103 shares. No derivative transactions were reported and no other changes in ownership were disclosed.
The filing is limited to this single transaction; it does not detail additional holdings or option grants. Form 4 timing complies with SEC rules, indicating the trade likely settled on, or shortly before, the reported date.